Cervel Neurotech, a privately held company developing a novel, non-invasive and non-pharmacologic therapy for depression, pain and other conditions, has completed a funding round of $14.1 million. The company’s existing investors, D. E. Shaw Ventures and Aberdare Ventures, participated in the equity financing.
You are browsing the archive for Aberdare Ventures - peHUB.
Aberdare Ventures said Tuesday that Mohit Kaushal has joined the firm as a partner. He will focus on Aberdare’s investments in technologies and services that will drive healthcare efficiency. Kaushal was most recently West Health’s chief strategy officer and EVP of business development.
RxAnte, a healthcare improvement company has raised Series A financing led by Aberdare Ventures with additional backing from the West Health Investment Fund. The financing will be used to further develop RxAnte’s proprietary technologies, commercialize its current offerings, and expand the company’s impact on the quality of medication use.
Lpath has appointed Daniel L. Kisner to its board of directors. Most recently, Kisner served as a partner at Aberdare Ventures and, prior to that, he was president and CEO of Caliper Technologies, leading its development from a start-up focused on microfluidic lab-on-a-chip technology to a publicly-traded organization. PRESS RELEASE Lpath, Inc. (OTCQB: LPTN), the [...]
PeHUB zeroed in on the years 2006 to 2009 to highlight the 10 funds with the worst IRRs. Six are vintage 2006, three come from vintage 2007.
Healthcare technology company MC10 has closed on a $2 million investment from Aberdare Ventures and added managing partner, Paul Klingenstein, to its board of directors. MC10 is headquartered in Cambridge, MA. PRESS RELEASE MC10 Inc. today announced it has closed on a $2 million investment from Aberdare Ventures and added managing partner, Paul Klingenstein, to [...]
Irvine, Calif.-based biotech company Aviir Inc. announced Tuesday that it had sealed an agreement with investors to raise up to $30 million. The financing includes an initial investment of $10 million and future investments of up to $20 million upon achieving certain milestones. Merck Global Health Innovation Fund led the round. Current investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners also participated.
Menlo Park, Calif.-based Nevro Corp., a neuromodulation company focused on relief of chronic pain, has sealed a whopping $58 million round led by new investor Johnson & Johnson Development Corporation. Existing shareholders Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners also participated. The money will go toward a clinical study in the US and to support the company’s commercialization strategy.
NxThera Inc., a St. Paul, Minn.-based medical devices company, has added $12.6 million in Series B financing. American Medical Systems Inc. led the round, and was joined by existing investors Arboretum Ventures, Aberdare Ventures and GDN Holdings. NxThera is developing medical technologies to treat a variety of endourology conditions.